
News|Articles|May 1, 2002
Health systems/plans share common coverage vision for Clarinex, OTC Claritin
Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
4
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
5


























